Related Experiment Video
Updated: Jul 6, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
[Nonalcoholic steatohepatitis: pathogenesis and treatment]
1Department of Internal Medicine, Hallym University College of Medicine, Anyang, Korea. sanghoon@hallym.or.kr
The Korean Journal of Hepatology
|March 28, 2008
Summary
Nonalcoholic fatty liver disease (NAFLD) progresses from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Understanding NASH pathogenesis and treatment is crucial due to rising obesity and diabetes rates.
Area of Science:
- Hepatology
- Metabolic Syndrome
- Gastroenterology
Context:
- Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions, including steatosis, nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma.
- NASH is an aggressive form of NAFLD, increasingly studied due to the prevalence of risk factors like obesity, type II diabetes mellitus, and dyslipidemia, particularly in Korea.
- The multifactorial pathogenesis of NASH involves insulin resistance, fatty acid accumulation, oxidant stress, mitochondrial dysfunction, and cytokine dysregulation.
Purpose:
- To review the current understanding of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
- To highlight the key factors contributing to NASH pathogenesis and progression.
- To discuss current therapeutic strategies and unresolved issues in NAFLD/NASH management.
Summary:
- NASH pathogenesis is complex, involving metabolic and inflammatory pathways, with genetic and environmental factors influencing progression.
- Lifestyle modifications are the primary treatment for NAFLD, though insulin-sensitizing drugs show potential for NASH.
- While promising, the efficacy of antioxidants and lipid-lowering agents in NASH requires further investigation.
Impact:
- Improved understanding of NASH pathogenesis can lead to targeted therapies.
- Addressing risk factors like obesity and diabetes is critical for NAFLD prevention and management.
- Further research is needed to resolve uncertainties regarding NASH natural history, pathogenesis, and treatment efficacy.
Related Concept Videos
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:24Chronic Pancreatitis I: Introduction
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:25Chronic Pancreatitis I: Introduction
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...